Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
CAS No. | 1428935-60-7 |
---|---|
Formulation | PBS buffer, pH 7.2 |
Isotype | Human IgG1 |
Source | CHO cells |
Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
Purity | 99.77% |
Protein concentration | 5.89mg/ml |
Endotoxin Level | ≤1 EU/mg |
Description | Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa. | ||||
---|---|---|---|---|---|
Targets |
|
||||
In vitro | The labeled radioligand shows good affinity to high PD-L1 expression cells and could be blocked with excess unlabeled intact durvalumab.[1] |
||||
In vivo | The peak tumor uptake of 124I-Durva-F(ab’)2 was close to 124I-Durva, but much earlier (5.29±0.42% ID/g for 124I-Durva-F(ab’)2 at 12 h vs 5.18±0.73% ID/g for 124I-Durva at 48 h). Compared with 124I-Durva, an accelerated blood clearance was observed for 124I-Durva-F(ab’)2, allowing for a higher tumor-to-background ratio.[1] |
Cell Assay: |
|
---|---|
Animal Study: |
|
References |
|
---|
Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab [ Am J Nucl Med Mol Imaging, 2024, 14(1):31-40] | PubMed: 38500749 |
Development of a highly sensitive chemiluminescence immunoassay using a novel signal-enhanced detection system for quantitation of durvalumab, an immune-checkpoint inhibitor monoclonal antibody used for immunotherapy of lung cancer [ Heliyon, 2023, 9(6):e15782] | PubMed: 37389074 |
Development of a highly sensitive chemiluminescence immunoassay using a novel signal-enhanced detection system for quantitation of durvalumab, an immune [ Heliyon, 2023, 9(6):e15782.] | PubMed: 37389074 |
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor [ Cancer Discov, 2022, 12(6):1482-1499] | PubMed: 35254416 |
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor [ Cancer Discov, 2022, 12(6):1482-1499] | PubMed: 35254416 |
SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling [ J Med Chem, 2022, 65(5):3879-3893] | PubMed: 35188766 |
Sunitinib potentiates the cytotoxic effect of electrochemotherapy in pancreatic carcinoma cells [ Mol Pharm, 2022, 10.1021/acs.molpharmaceut.2c00084] | PubMed: 35244407 |
Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer [ Cancer Commun (Lond), 2021, 41(6):511-527] | PubMed: 33939321 |
Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction [ J Med Chem, 2021, 64(11):7390-7403] | PubMed: 34056906 |
Galvanotactic Migration of Glioblastoma and Brain Metastases Cells [ J Med Chem, 2021, 64(15):11614-11636] | PubMed: 34313116 |
FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.
Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.